These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

364 related articles for article (PubMed ID: 16322312)

  • 1. Combination immunotherapy with clinical-scale enriched human gammadelta T cells, hu14.18 antibody, and the immunocytokine Fc-IL7 in disseminated neuroblastoma.
    Otto M; Barfield RC; Martin WJ; Iyengar R; Leung W; Leimig T; Chaleff S; Gillies SD; Handgretinger R
    Clin Cancer Res; 2005 Dec; 11(23):8486-91. PubMed ID: 16322312
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immune response of human propagated gammadelta-T-cells to neuroblastoma recommend the Vdelta1+ subset for gammadelta-T-cell-based immunotherapy.
    Schilbach K; Frommer K; Meier S; Handgretinger R; Eyrich M
    J Immunother; 2008; 31(9):896-905. PubMed ID: 18832998
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immunotherapeutic strategies in neuroblastoma: antitumoral activity of deglycosylated Ricin A conjugated anti-GD2 antibodies and anti-CD3xanti-GD2 bispecific antibodies.
    Manzke O; Russello O; Leenen C; Diehl V; Bohlen H; Berthold F
    Med Pediatr Oncol; 2001 Jan; 36(1):185-9. PubMed ID: 11464879
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Human gammadelta T cells from G-CSF-mobilized donors retain strong tumoricidal activity and produce immunomodulatory cytokines after clinical-scale isolation.
    Otto M; Barfield RC; Iyengar R; Gatewood J; Müller I; Holladay MS; Houston J; Leung W; Handgretinger R
    J Immunother; 2005; 28(1):73-8. PubMed ID: 15614047
    [TBL] [Abstract][Full Text] [Related]  

  • 5. CD16+ gammadelta T cells mediate antibody dependent cellular cytotoxicity: potential mechanism in the pathogenesis of multiple sclerosis.
    Chen Z; Freedman MS
    Clin Immunol; 2008 Aug; 128(2):219-27. PubMed ID: 18501678
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Novel bispecific antibodies increase γδ T-cell cytotoxicity against pancreatic cancer cells.
    Oberg HH; Peipp M; Kellner C; Sebens S; Krause S; Petrick D; Adam-Klages S; Röcken C; Becker T; Vogel I; Weisner D; Freitag-Wolf S; Gramatzki M; Kabelitz D; Wesch D
    Cancer Res; 2014 Mar; 74(5):1349-60. PubMed ID: 24448235
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Enhanced activity of hu14.18-IL2 immunocytokine against murine NXS2 neuroblastoma when combined with interleukin 2 therapy.
    Neal ZC; Yang JC; Rakhmilevich AL; Buhtoiarov IN; Lum HE; Imboden M; Hank JA; Lode HN; Reisfeld RA; Gillies SD; Sondel PM
    Clin Cancer Res; 2004 Jul; 10(14):4839-47. PubMed ID: 15269160
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The GD2-specific 14G2a monoclonal antibody induces apoptosis and enhances cytotoxicity of chemotherapeutic drugs in IMR-32 human neuroblastoma cells.
    Kowalczyk A; Gil M; Horwacik I; Odrowaz Z; Kozbor D; Rokita H
    Cancer Lett; 2009 Aug; 281(2):171-82. PubMed ID: 19339105
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Redirected T-cell cytotoxicity to epithelial cell adhesion molecule-overexpressing adenocarcinomas by a novel recombinant antibody, E3Bi, in vitro and in an animal model.
    Ren-Heidenreich L; Davol PA; Kouttab NM; Elfenbein GJ; Lum LG
    Cancer; 2004 Mar; 100(5):1095-103. PubMed ID: 14983507
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Combination therapy with interleukin-2 and antitumor monoclonal antibodies.
    Sondel PM; Hank JA
    Cancer J Sci Am; 1997 Dec; 3 Suppl 1():S121-7. PubMed ID: 9457407
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Zoledronate sensitizes neuroblastoma-derived tumor-initiating cells to cytolysis mediated by human γδ T cells.
    Nishio N; Fujita M; Tanaka Y; Maki H; Zhang R; Hirosawa T; Demachi-Okamura A; Uemura Y; Taguchi O; Takahashi Y; Kojima S; Kuzushima K
    J Immunother; 2012 Oct; 35(8):598-606. PubMed ID: 22996365
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Oral (1-->3),(1-->4)-beta-D-glucan synergizes with antiganglioside GD2 monoclonal antibody 3F8 in the therapy of neuroblastoma.
    Cheung NK; Modak S
    Clin Cancer Res; 2002 May; 8(5):1217-23. PubMed ID: 12006541
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A novel five-colour flow cytometric assay to determine NK cell cytotoxicity against neuroblastoma and other adherent tumour cells.
    Klöss S; Bochennek K; Huenecke S; Zimmermann SY; Kuçi S; Müller T; Wels WS; Klingebiel T; Esser R; Koehl U
    J Immunol Methods; 2007 Aug; 325(1-2):140-7. PubMed ID: 17663991
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Type I IFN-mediated enhancement of anti-leukemic cytotoxicity of gammadelta T cells expanded from peripheral blood cells by stimulation with zoledronate.
    Watanabe N; Narita M; Yokoyama A; Sekiguchi A; Saito A; Tochiki N; Furukawa T; Toba K; Aizawa Y; Takahashi M
    Cytotherapy; 2006; 8(2):118-29. PubMed ID: 16698685
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Plasmodium berghei XAT: contribution of gammadelta T cells to host defense against infection with blood-stage nonlethal malaria parasite.
    Kobayashi F; Niikura M; Waki S; Matsui T; Fujino T; Tsuruhara T; Kamiya S
    Exp Parasitol; 2007 Dec; 117(4):368-75. PubMed ID: 17601562
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Innate anti-breast cancer immunity of apoptosis-resistant human gammadelta-T cells.
    Guo BL; Liu Z; Aldrich WA; Lopez RD
    Breast Cancer Res Treat; 2005 Sep; 93(2):169-75. PubMed ID: 16187237
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Anti-neuroblastoma effect of ch14.18 antibody produced in CHO cells is mediated by NK-cells in mice.
    Zeng Y; Fest S; Kunert R; Katinger H; Pistoia V; Michon J; Lewis G; Ladenstein R; Lode HN
    Mol Immunol; 2005 Jul; 42(11):1311-9. PubMed ID: 15950727
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Synergistic interleukin-18 and low-dose interleukin-2 promote regression of established murine neuroblastoma in vivo.
    Redlinger RE; Mailliard RB; Lotze MT; Barksdale EM
    J Pediatr Surg; 2003 Mar; 38(3):301-7; discussion 301-7. PubMed ID: 12632339
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Flow cytometric assessment of autologous gammadelta T cells in patients with acute myeloid leukemia: potential effector cells for immunotherapy?
    Aswald JM; Wang XH; Aswald S; Lutynski A; Minden MD; Messner HA; Keating A
    Cytometry B Clin Cytom; 2006 Nov; 70(6):379-90. PubMed ID: 16977635
    [TBL] [Abstract][Full Text] [Related]  

  • 20. gammadelta T cells: a new frontier for immunotherapy?
    Lamb LS; Lopez RD
    Biol Blood Marrow Transplant; 2005 Mar; 11(3):161-8. PubMed ID: 15744234
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.